New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXIII)

Monday, October 23
8:45-10:30 AM

Vancouver, BC

Chair: Paul W. Armstrong

Co-Chair: Justin Ezekowitz

2017 Sponsors
of New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXIII)

This accredited symposium was co-developed with the Canadian Cardiovascular Society, Mazankowski Alberta Heart Institute/University of Alberta, Canadian VIGOUR Centre, AstraZeneca Canada Inc., Bayer Inc., Merck Canada Inc. and Novartis Pharmaceuticals Canada Inc. and was planned to achieve scientific integrity, objectivity and balance.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.

Live educational activities, occurring in Canada, recognized by the Royal College of Physicians and Surgeons of Canada as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists (UEMS) eligible for ECMEC credits.



New Concepts in Heart Failure and Atrial Fibrillation: Beyond 2000 (XXIII)


Monday, October 23, 2017




Learning Objectives

  • Develop a management strategy for patients with heart failure across a spectrum of ejection fractions and with or without atrial fibrillation.
  • Formulate how to incorporate sacubitril/valsartan and ivabradine into clinical practice.
  • Apply an appropriate strategy for adding or deleting older therapies in heart failure.
  • Craft an evidence-based approach to modifying diabetes-related medications for patients with or at risk for heart failure.
  • Incorporate new knowledge in acute and chronic heart failure into current patient care.